---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-125092"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:50:25.962738+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Announces Positive Interim Phase 1 Data for WVE-007 in Obesity Trial

## Summary
- Single 240 mg dose of WVE-007 reduced visceral fat by 14% (placebo-adjusted, p<0.05) at six months.
- WVE-007 showed preservation of lean mass (+2%) and waist circumference reduction (-3%) at six months.
- Phase 2a portion of INLIGHT in higher BMI (35-50 kg/m2) to initiate in 2Q 2026.
- WVE-007 continues to be generally safe and well tolerated with no severe TEAEs.

## SEC filing metadata
- accession: 0001193125-26-125092
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312526125092/0001193125-26-125092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312526125092/d17239d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-125092
- JSON: https://secwatch.observer/filing/0001193125-26-125092.json
- Plain text: https://secwatch.observer/filing/0001193125-26-125092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.